According to our (Global Info Research) latest study, the global Human Prothrombin Complex Concentrate market size was valued at US$ 1510 million in 2025 and is forecast to a readjusted size of US$ 2944 million by 2032 with a CAGR of 10.1% during review period.
Human prothrombin complex concentrate, also known as factor IX complex, is a plasma-derived coagulation factor extract, which was originally used to treat factor IX deficiency, because PCC also contains coagulation factors II, VII, and X, so PCCs are more commonly used Recommended for correcting coagulation abnormalities caused by warfarin. It is mainly used for the treatment of congenital and acquired coagulation factor II, VII, IX, and X deficiency (single or combined deficiency).In 2024, global Human prothrombin complex concentrate production reached approximately 4.73 m units, with an average global market price of around US$ 280 perunit.The average gross profit margin of this product is 80%.
The global market for Human Prothrombin Complex Concentrate is primarily driven by the expansion of clinical applications for plasma-derived products, heightened awareness of severe bleeding management, and the growing need for anticoagulant reversal therapy. With an aging population and increased use of anticoagulants, demand for rapid and safe hemostatic solutions continues to rise. Increased investments in trauma care systems and perioperative bleeding management for cardiovascular and hepatic patients across various countries are expanding the market potential for PCC products. Meanwhile, advances in recombinant technology and viral inactivation processes have enhanced product safety and accessibility, further propelling global market growth.
The development of the PCC market remains constrained by the limited availability of plasma resources, the complexity of production processes, and stringent regulatory requirements. Imbalances in plasma collection systems lead to supply chain instability, while manufacturing involves multiple high-precision steps such as viral inactivation, purification, and lyophilization, requiring significant technological expertise and cost investment. Differences in regulatory approval pathways, ethical standards, and drug traceability systems across countries may further delay product commercialization. Additionally, the emergence of recombinant clotting factors and synthetic hemostatic substitutes poses potential competition in specific clinical applications, raising the bar for innovation and compliance among traditional PCC manufacturers.
Downstream demand for PCC primarily originates from hospital emergency departments, intensive care units, and surgical applications. With the increasing volume of cardiovascular interventions, hepatobiliary surgeries, and trauma procedures, clinical use of PCC continues to expand. Reversal of anticoagulant-induced bleeding, particularly from warfarin therapy, has become one of its main use cases. Moreover, PCC usage is growing steadily in emergency and perioperative coagulation management. In developing regions, accessibility to plasma-derived products is improving, leading to rising import and local production demand for PCC, alongside a diffusion trend from tertiary hospitals to regional medical institutions.
The primary upstream raw material for PCC production is high-quality human plasma, whose stable supply is essential for maintaining industry competitiveness. Plasma must undergo rigorous screening, separation, and viral inactivation processes, and instability at any stage can impact product yield and safety. Global plasma collection is concentrated among a few major suppliers, and regional regulatory variations may lead to uneven supply. In addition to plasma, the production process requires auxiliary materials such as chromatographic resins, filtration membranes, and lyoprotectants, whose purity and batch consistency are critical for quality assurance. As the industry moves toward higher purity and safety standards, manufacturers are increasingly strengthening raw material traceability and consistency management across the supply chain.
This report is a detailed and comprehensive analysis for global Human Prothrombin Complex Concentrate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Prothrombin Complex Concentrate market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Human Prothrombin Complex Concentrate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Human Prothrombin Complex Concentrate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Human Prothrombin Complex Concentrate market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Prothrombin Complex Concentrate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Prothrombin Complex Concentrate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Octapharma, Prothya Biosolutions, Takeda, RAAS, Hualan Bio, BOHUI, NUOYI BIO, SINOPHARM, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Human Prothrombin Complex Concentrate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Market segment by Composition
3-Factor PCC
4-Factor PCC
Recombinant Coagulation Complex
Other
Market segment by Manufacturing Process
Plasma-Derived
Recombinant Bioengineered
Market segment by Application
Hemophilia B
Vitamin K Deficiency
Other
Major players covered
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
RAAS
Hualan Bio
BOHUI
NUOYI BIO
SINOPHARM
Guangdong Weilun
Weiguang Bio
Kangbo Bio
Huarun Boya
Taibang Biologic
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Prothrombin Complex Concentrate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Prothrombin Complex Concentrate, with price, sales quantity, revenue, and global market share of Human Prothrombin Complex Concentrate from 2021 to 2026.
Chapter 3, the Human Prothrombin Complex Concentrate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Prothrombin Complex Concentrate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Human Prothrombin Complex Concentrate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Prothrombin Complex Concentrate.
Chapter 14 and 15, to describe Human Prothrombin Complex Concentrate sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Human Prothrombin Complex Concentrate. Industry analysis & Market Report on Human Prothrombin Complex Concentrate is a syndicated market report, published as Global Human Prothrombin Complex Concentrate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Human Prothrombin Complex Concentrate market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.